Skip to content
drillr.ai
Sign up

MRK

Merck & Co., Inc.

NYSE · Healthcare · Drug Manufacturers - General · US

$148.34
+2.53%
Ask drillr

  • Oct 7, 2026, 11:00 UTC

    PeptiDream received an undisclosed milestone fee from Merck & Co., Inc. following progress in a jointly developed PCC program.

    Source:

  • Oct 5, 2026, 14:23 UTC

    Vaxcyte shares spiked 57% after its lead vaccine candidate showed trial results positioning it against Pfizer and Merck.

    Source:

  • Oct 1, 2026, 10:45 UTC

    Merck announced it will hold its third-quarter 2026 sales and earnings conference call on October 29, 2026.

    Source:

  • Oct 1, 2026, 05:30 UTC

    The Ad Council launched "The Secret to Motherhood," a maternal mental health campaign under its "Love, Your Mind" initiative, with new public service announcements titled "What's Her Secret?" in English and Spanish.

    Source:

  • Sep 30, 2026, 12:26 UTC

    Merck announced that its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa.

    Source:

  • Sep 29, 2026, 18:15 UTC

    MSD, in partnership with Africa Health Business, held a high-level policy roundtable in Abuja on accelerating cervical cancer elimination in Nigeria.

    Source:

  • Sep 29, 2026, 08:29 UTC

    China's National Medical Products Administration approved Merck's subcutaneous formulation of the PD-1 inhibitor pembrolizumab (Keytruda) for 19 solid tumor indications, making it the first and only subcutaneously administered PD-1 inhibitor approved in China.

    Source:

  • Sep 28, 2026, 20:45 UTC

    Merck discontinued its antibiotic Recarbrio from the U.S. market earlier in September 2026, ending supply of the three-drug combination injection approved seven years earlier for serious infections.

    Source:

  • Sep 28, 2026, 10:55 UTC

    Shanghai SPR Therapeutics granted Merck exclusive worldwide rights to develop, manufacture and commercialize its preclinical oral KRAS G12D (ON) inhibitor SPR2015 in a deal worth up to $2.13 billion, including a $400 million upfront payment.

    Source:

  • Sep 28, 2026, 10:48 UTC

    Merck & Co. granted SciBrunch an exclusive worldwide license to develop, manufacture and commercialize SPR2015, with SciBrunch to receive a $400 million upfront payment and total potential consideration of $2.13 billion including the upfront.

    Source:

  • Sep 28, 2026, 10:47 UTC

    Merck & Co. will record a $400 million pre-tax charge in the third quarter of 2026.

    Source:

  • Sep 28, 2026, 09:56 UTC

    MSD appointed Vidhya Sundaram as Associate Vice President of Global Technology Centres and Lead of its Hyderabad Tech Centre.

    Source:

  • Sep 28, 2026, 06:32 UTC

    Daiichi Sankyo withdrew its US accelerated approval application for the small cell lung cancer drug ifinatamab deruxtecan after determining it did not meet the conditions required for approval.

    Source:

  • Sep 28, 2026, 05:30 UTC

    Kenya is preparing to manufacture alimatravir, an investigational once-monthly oral HIV-prevention medicine developed by MSD, according to President William Ruto.

    Source:

  • Sep 27, 2026, 16:00 UTC

    US Senators Elizabeth Warren, Ron Wyden and Richard Blumenthal questioned Health Secretary Robert F. Kennedy Jr. on September 24 over an alleged break in his ethics pledges concerning Gardasil litigation interests.

    Source:

  • Sep 25, 2026, 20:30 UTC

    Daiichi Sankyo and Merck voluntarily withdrew the U.S. Biologics License Application seeking accelerated approval of ifinatamab deruxtecan for adults with extensive-stage small cell lung cancer whose disease progressed on or after platinum-based chemotherapy.

    Source:

  • Sep 24, 2026, 21:58 UTC

    The FDA approved Merck & Co.'s Welireg (belzutifan) in combination with Eisai's Lenvima (lenvatinib) for advanced clear-cell renal cell carcinoma following treatment with a PD-(L)1 inhibitor.

    Source:

  • Sep 24, 2026, 10:45 UTC

    Merck announced that Remigromig met its primary endpoint in a trial for diabetic macular edema (DME).

    Source:

  • Sep 23, 2026, 23:59 UTC

    Summit Therapeutics and Akeso revealed new study findings for ivonescimab that impressed Wall Street amid dueling data with a rival Merck medication.

    Source:

  • Sep 23, 2026, 12:17 UTC

    Justin Gunn was appointed President, Endocrinology at Corcept Therapeutics effective October 1, 2026.

  • Sep 22, 2026, 10:45 UTC

    The U.S. FDA approved an update to the U.S. product label for Merck's WINREVAIR (sotatercept-csrk) to include data from the Phase 3 HYPERION trial in adults recently diagnosed with pulmonary arterial hypertension.

    Source:

  • Sep 21, 2026, 10:45 UTC

    Japan's Ministry of Health, Labour and Welfare approved Merck's KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous administration across all KEYTRUDA indications approved in Japan.

    Source:

  • Sep 10, 2026, 08:21 UTC

    China's National Medical Products Administration approved Merck's Keytruda (pembrolizumab) for expanded use in early-stage high-risk triple-negative breast cancer in China.

    Source:

  • Sep 4, 2026, 00:42 UTC

    Merck announced that China's National Medical Products Administration approved its PD-1 inhibitor Keytruda (pembrolizumab) for the neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma in adult patients with PD-L1 expression (CPS ≥1).

    Source:

  • Aug 26, 2026, 04:45 UTC

    Four Democratic senators, led by Elizabeth Warren, sent a letter to Health Secretary Robert F. Kennedy Jr. questioning his disclosures regarding a $50 million settlement by Merck over Gardasil vaccine litigation, in which Kennedy had a financial interest before taking office.

    Source:
← PreviousPage 2Next →